Clinical Trials
13
Active:3
Completed:5
Trial Phases
3 Phases
Phase 1:4
Phase 2:1
Phase 3:7
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 3
7 (58.3%)Phase 1
4 (33.3%)Phase 2
1 (8.3%)To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
Phase 2
Active, not recruiting
- Conditions
- HPV InfectionHPV-Related CarcinomaHPV-Related Intraepithelial NeoplasiaGenital Wart
- Interventions
- Biological: Medium dose for 15-HPV vaccineBiological: High dose for 15-HPV vaccineBiological: PlaceboBiological: 9-HPV vaccine
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT06756269
- Locations
- 🇨🇳
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, Guangxi, China
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
Phase 3
Active, not recruiting
- Conditions
- HPV-Related CarcinomaPenile CancerAIN3Genital WartAnal CancerPIN3AIN1PIN2PIN-1AIN2
- Interventions
- Biological: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)Biological: Placebo
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Target Recruit Count
- 9000
- Registration Number
- NCT06465914
- Locations
- 🇨🇳
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, Guangxi, China
🇨🇳Hunan Center for Disease Control and Prevention, Changsha, Hunan, China
🇨🇳Shanxi Provincial Disease for Control and Prevention, Taiyuan, Shanxi, China
A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years
Phase 1
Active, not recruiting
- Conditions
- Genital WartHPV InfectionHPV-Related CarcinomaHPV-Related Intraepithelial Neoplasia
- Interventions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT06454175
- Locations
- 🇨🇳
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Guangxi, China
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
Phase 3
Terminated
- Conditions
- CIN2Vin IIAISCervical CancerVin IVin IIIVain IVain IIIGenital WartCIN1
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Target Recruit Count
- 3131
- Registration Number
- NCT05584332
- Locations
- 🇨🇳
Yi M, Liuzhou, Guangxi, China
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
Phase 1
Completed
- Conditions
- Anal CancerPenile CancerPIN-1AIN2PIN-2PIN-3AIN1AIN3Genital Wart
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT05518201
- Locations
- 🇨🇳
Center for Disease Control and Prevention, Mianzhu, Sichuan, China
- Prev
- 1
- 2
- 3
- Next
News
No news found